This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Board meeting on Oct 29 to approve Q2 and H1FY27 results
AMBUJACEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty 100 and 2.9 pts more than its Cement & Cement Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board meeting scheduled for October 29, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026 (Q2 and H1FY27). Trading window for dealing in securities is closed from October 1, 2026 and will reopen 48 hours after results announcement. An investor and analyst call is scheduled the same day at 4:30 PM IST, led by the CEO and CFO.
Routine pre-results filing. Q2 and H1FY27 numbers plus business outlook due on October 29, 2026.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹9,197 Cr | ₹9,174 Cr | +0.2% |
| Operating profit | ₹320.0 Cr | ₹798.9 Cr | −59.9% |
| Profit after tax | ₹236.0 Cr | ₹2,302 Cr | −89.7% |
| EBITDA margin | 12.9% | 16.8% | −3.9 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.